Department of Pathology
  Brigham and Women's Hospital
  A teaching Affliate of Harvard Medical School
Login Skip Navigation Links
  Skip Navigation Links
HomeExpand Home





Announcement

Submit new announcement
Scott J. Rodig, M.D.,Ph.D.

Associate Professor of Pathology, Harvard Medical School
Attending physician: Hematopathology, Hematology Laboratory, and Molecular Diagnostic services
Associate Pathologist: Specialized Histopathology Core Facility, Dana-Farber/ Harvard Cancer Center
Associate Pathologist: Tissue Microarray and Imaging Core Facility, Dana-Farber/ Harvard Cancer Center
Academic Activities:
My interests encompass translational and clinical research in hematopathology and molecular pathology with an emphasis on the development, validation, and implementation of new biomarkers to improve diagnostic practice.
Office
Amory 3,
75 Francis Street
Boston,MA 02115
Email1: srodig@partners.org
LAb
Thorn 603
15 Shattuck Street
Boston ,MA 02115
Email1:
Education and Training:

Graduate School 1991 - 1998 : Washington University School of Medicine Ph.D.
Medical School 1991 - 1998 : Washington University School of Medicine M.D.
Residency 1998 - 2001 : Brigham and Women's Hospital
Fellowship 2000 - 2001 : Brigham and Women's Hospital

Clinical Specialties:
  • Hematopathology
  • Hematology
  • Molecular Diagnostics
Research Interests:
  • Leukemia
  • Lymphoma
Publication:
  1. Meraz MA, White JM, Sheehan KCF, Bach EA, Rodig, SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Cambell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD. Targeted disruption of the STAT1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996; 84: 431-442.
  2. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CA, King KL, Sheehan KCF, Yin L, Pennica D, Johnson EM, Schreiber RD. Disruption of the JAK1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998; 93: 373-383.
  3. Migone TS, Rodig SJ, Cacalano NA, Berg M, Schreiber RD, Leonard WJ. Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3-kinase recruitment and phosphorylation. Mol Cell Bio. 1998; 18 (11): 6416-22.
  4. Satoskar AR, Rodig S, Telford III SR, Satoskar AA, Ghosh SK, von Lichtenberg F, David JR. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immun. 2000; 30:834-839.
  5. Hu J, Roy SK, Shapiro PS, Rodig SR, Reddy SP, Platanias LC, Schreiber RD, Kalvakolanu DV. ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. J Biol Chem, 2001;276(1):287-97.
  6. Rodig SJ, Jones D, Shahsafaei A, Dorfman DM. CCR6 is a functional chemokine receptor that serves to identify select B-cell non-Hodgkin's lymphomas. Hum Path, 2002; 33(12):1227-33.
  7. Rodig SJ, Savage KJ, Nguyen V, Pinkus GS, Shipp MA, Aster JC, Kutok JL. TRAF-1 expression and c-Rel activation distinguish classical Hodgkin lymphoma from other morphologically or immunophenotypically similar forms of malignant lymphoma. Am J Surg Path, 2005; 29(2):196-203.
  8. Rodig SJ, Shahsafaei A, Dorfman DM. The CD45 isoform B220 identifies select subsets of human B cells and B cell lymphoproliferative disorders. Hum Path, 2005; 36(1):51-7.
  9. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM. BAFF-R, the major B cell activating factor receptor, is expressed on the majority of mature B cells and B cell lymphoproliferative disorders. Human Pathol, 2005; 36(10):1113-9.
  10. Rodig SJ, Healey BM, Pinkus GS, Kuo FC, Cin PD, Kutok JL. Mantle cell lymphoma arising within primary nodal marginal zone lymphoma: unique presentation of two uncommon B-cell lymphoproliferative disorders. Cancer Genet & Cytogenet, 2006;171(1): 44-51
  11. Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dofman DM, Dong HY, Shipp MA, Kutok JL. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of Alemtuzumab (CAMPATH-1H). Clin Cancer Res, 2006;12(23): 7174-9.
  12. Rodig SJ, Savage KJ, LaCase AS, Weng AP, Harris NL, Shipp MA, Hsi ED, Gascoyne RD, Kutok JL. Expression of TRAF-1 and nuclear c-Rel distinguishes primary mediastinal large B cell lymphoma from othe types of diffuse large B cell lymphoma. Am J Surg Pathol, 2007; 31(1): 106-112.
  13. Juszczynski P, Ouyang J, Monit S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA. The AP1-dependent secretion of Galectin-1 by Reed-Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. PNAS, 2007; 104(32):13134-9.
  14. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 2007; 450(7171):903-7.
  15. Rodig SJ, Payne EG, Degar BA, Rollins B, Feldman AL, Jaffe ES, Androkites A, Silverman LB, Longtine JA, Kutok JL, Fleming MD, Aster JC. Fatal Langerhans cell histiocytosis following T-ALL: Clonally related neoplasms with persistent expression of constitutively active NOTCH1. Am J Hematol., 2008; 83:116-21.
  16. Rodig SJ, Vergilio J, Shahsafaei A, Dorfman DM. Characteristic Expression Patterns of TCL1, CD38, and CD44 Identify Aggressive Lymphomas Harboring a MYC Translocation. Am J Surg Pathol., 2008; 32(1):113-122.
  17. Rodig SJ, Ouyang J, Juszczynski P, Currie T, Law K, Neuberg DS, Rabinovich GA, Shipp MA, Kutok JL. AP1-dependent Galectin-1 Expression Delineates Classical Hodgkin and Anaplastic Large Cell Lymphomas from Other Lymphoid Malignancies with Shared Molecular Features. Clinc Cancer Res, 2008; 14(11):3338-44.
  18. Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdai R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH. Targeting CD22 reprograms B cells and reverses autoimmune diabetes. Diabetes, 2008; 57(11):3013-24.
  19. Babbe H, McMenamin J, Hobeika E, Wang J, Rodig SJ, Reth M, Leder P. Genomic instability resulting from Blm-deficiency compromises development, maintenance, and function of the B cell lineage. J Immun. 2009; 182(1): 347-360.
  20. Cornejo MG, Kharas MG, Werneck MB, LeBras S, Moore SA, Ball B, Beylot-Barry M, Rodig SJ, Aster JC, Lee BH, Cantor H, Merlio J-P, Gilliland DG, Mercher T. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplant models. Blood, 2009; 113(12): 2746-54.
  21. Willis SN, Mallozzi SS, Rodig SJ, Cronk KM, McArdel SL, Caron T, Pinkus GS, Lovato L, Shampain KL, Anderson DE, Anderson RC, Bruce JN, O’Connor KC. The microenviroment of germ cell tumors harbor a prominent antigen-driven humoral response. J Immun., 2009; 182(5): 3310-7.
  22. Yang J, Bielenberg D, Rodig S, Doiron R, Clifton MC, Kung A, Strong RK, Zurakowski D, Moses M. Lipocalin 2 promotes breast cancer progression. PNAS, 2009; 106(10): 3913-8
  23. Riccio A, Li Y, Moon J, Kim K-S, Gapon S, Yao GL, Tsvetkov E, Rodig SJ, Meloni EG, Carlezon Jr WA, Bolshakov VY, Clapham DE. Essential role for TRPC5 in amygdala function and fear-related behavior. Cell, 2009; 137(4): 761-772.
  24. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Admane S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ. Clinical Features and Outcome of Patients with Non-Small Cell Lung Cancer Harboring EML4-ALK, J. Clin. Onc., 2009; 27(26):4247-53.
  25. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, Bailey D, Fletcher JA, Loda M, Rodig SJ, Dal Cin P, Fletcher CD. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme, J. Path., 2009; 218(3):292-300.
  26. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne P, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR. Unique Clinicopathologic Features Characterize ALK-rearranged Lung Adenocarcinoma in the Western Population. Clin. Cancer Res., 2009; 15(16): 5216-23.
  27. Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS, Roughan JE, Blewett MM, Bruck W, Hafler DA, O’Connor KC. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain, 2009; 132(12): 3318-28.
  28. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R. Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes. J Immun., 2009; 183(2):993-1004.
  29. Bertrand KA, Spiegelman D, Aster JC, Altshul LA, Korrick SA, Rodig SJ, Zhang SM, Kurth T, Laden F. Plasma organochlorine levels and risk of non-Hodgkin lymphoma in the Physicians' Health Study. Epidemiology, 2010; 21(2):172-180.
  30. Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, Brown JR, Mitsiades C, Dibuona M, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Stone RM, Xiao Y, Piciocchi A, Griffin JD, Anderson KC, Ritz J, Foa R, Aster JC, Frank DA, Weinstock DM. Dysregulation of the cytokine receptor CRLF2 in B-cell acute lymphoblastic leukemia. PNAS, 2010; 107(1): 252-7
  31. Ghobrial IM, Roccaro A, Hong F, Heller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Azab F, Azab A, Rodig S, Warren D, Harris B, Varticovski L, Sportelli E, Leleu X, Anderson K, Richardson P. Clinical and translational studies of a phase II trial of a novel oral Akt inhibitor Perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin. Cancer Res., 2010; 16(3): 1033-41.
  32. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, Cohen DW, Johnson BE, Janne PA, Iafrate AJ, Rodig SJ. A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-rearranged Lung Adenocarcinomas by Standard Immunohistochemistry. Clin. Cancer Res., 2010; 16(5): 1561-71.*
  33. Juszczynski P, Rodig SJ*, Ouyang J, O'Donnell E, Takeyama K, Mlynarski W, Mycko K, Szczepanski T, Gaworczyk A, Krivtsov A, Faber J, Sinha A, Rabinovich G, Armstrong S, Kutok JL, Shipp MA. MLL-rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-binding Protein, Galectin-1. Clin.Cancer Res., 2010, 16(7): 2122-30.
  34. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Patel K, Gorgun G, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi N, Anderson K, Raje N. Dual inhibition of AKT/mTOR pathway by nab-rapamycin and perifosine induces anti-tumor activity in multiple myeloma. Mol. Cancer Therap., 2010, 9(4) 963-75.
  35. Spivey K, Banyard J, Solis L, Wistuba I, Barletta J, Gandhi L, Feldman H, Rodig S, Chirieac L, Zetter B. Collagen XXIII- a potential biomarker for the detection of primary and recurrent non- small cell lung cancer. CEBP., 2010 19(5):1362-72.
  36. Ruzinova M, Caron T, Rodig SJ. Altered Subcellular Localization of c-Myc Protein Identifies Aggressive B-cell Lymphomas Harboring a c-MYC translocation. Am J Surg Pathol., 2010, May 3.
  37. O’Brien K, Alberich-Jorda M, Yadav N, Kocher O, DiRuscio A, Ebralidze A, Levantini E, Sng NJL, Bhasin M, Caron T, Kim D, Steidl U, Huang G, Halmos B, Rodig SJ, Bedford MT, Tenen DG, Kobayashi S. CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells. Development. 2010, 137:2147-56.
  38. Vergani A, D’Addio F, Jurewicz M, Petrelli A, Watanabe T, Liu K, Law K, Schuetz C, Carvello M, Osenigo E, Deng S, Rodig S, Ansari J, Staudacher, C, Abdi R, Williams J, Markman J, Atkinson M, Sayegh M, Fiorina P. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes, in press.
  39. Green M, Monti S, Rodig S, Juszczynski P, Currie T, O’Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub T, Kutok JL, Shipp MA. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular Sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood, in press.
  40. Runnels J, Carlson AL, Pitsillides C, Thompson B, Wu J, Spencer JA, Kohler JMJ, Azab A, Moreau A-S, Rodig SJ, Kung A, Anderson KC, Ghobrial IM, Lin CP. Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J. Bio. Optics., in press.
  41. Koduru S, Kumar L, Massaad M, Ramesh N, LeBras S, Ozcan S, Oyoshi M, Kaku M, Fujiwara Y, Kremer L, King S, Fuhlbrigge R, Rodig S, Sage P, Carman C, Alcaide P, Luscinskas F, Geha R. CIP4 is essential for integrin dependent T cell trafficking. PNAS, in press.
  42. Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin PS, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Janne PA, Maki RG, Demetri GD, Shapiro GI. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. NEJM, in press.
<October 2017>
SuMoTuWeThFrSa
24252627282930
1234567
891011121314
15161718192021
22232425262728
2930311234


<Friday, October 20, 2017>
8:00 AM
Dr. Maria Kuba, Dr. Yi Daniel Li
Cotran Conference Center
9:15 AM

Autopsy suite
12:00 PM

GYN 14-headed scope
1:00 PM
Dr. Christopher Fletcher
Cotran Conference Center
Copyright 2008 - 2017, BWH Pathology, All rights reserved.